ArticleCureus2025
A Case of Pneumocystis jirovecii Pneumonia Requiring Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO) Management in a Young Patient With Aortic Inflammation Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumocystis jirovecii pneumonia (PCP) occurs in immunocompromised patients. It is classified into cases in human immunodeficiency virus (HIV)-positive (HIV-PCP) patients and HIV-negative (non-HIV-PCP) patients. Non-HIV-PCP is associated with particularly poor prognosis, and case reports using veno-venous extracorporeal membrane oxygenation (VV-ECMO) are scarce. This case report describes a 25-year-old female patient with a history of taking multiple immunosuppressive medications who was diagnosed with PCP. She received antibiotic treatment, but her hypoxemia worsened, and she was admitted to the intensive care unit. Non-invasive respiratory therapy failed to improve hypoxemia, so endotracheal intubation and mechanical ventilation were initiated. However, adequate oxygenation was not achieved. Despite immunodeficiency, the patient was young and had no other organ failure. Therefore, the initiation of VV-ECMO was decided upon. After 20 days of VV-ECMO management, there were no major complications, and respiratory abnormalities improved. In cases of non-HIV-PCP presenting with life-threatening respiratory failure, VV-ECMO initiation should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.